MX2009003417A - Metodo de inmunizacion contra los 4 serotipos de dengue. - Google Patents
Metodo de inmunizacion contra los 4 serotipos de dengue.Info
- Publication number
- MX2009003417A MX2009003417A MX2009003417A MX2009003417A MX2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A
- Authority
- MX
- Mexico
- Prior art keywords
- dengue
- serotype
- dose
- series
- dengue serotypes
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title abstract 6
- 206010012310 Dengue fever Diseases 0.000 title abstract 6
- 208000025729 dengue disease Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 4
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se relaciona a un método para inducir una protección contra los 4 serotipos de dengue en un paciente, que comprende: (a) una primera serie de administraciones (i) de una dosis de un virus de dengue vacunal de un primer serotipo y una dosis de un virus de dengue vacunal de un segundo serotipo, y (ii) de una dosis de un virus de dengue vacunal de un tercer serotipo y una dosis de un virus de dengue vacunal de un cuarto serotipo, y (b) una segunda serie de administraciones de las dosis (i) y (ii), en donde las dosis (i) y (ii) se administran simultáneamente en sitios anatómicos separados, y en donde la segunda serie se administra por lo menos 30 días y a lo más 12 meses después de la primera serie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0608660A FR2906724B1 (fr) | 2006-10-04 | 2006-10-04 | Methode d'immunisation contre les 4 serotypes de la dengue. |
PCT/FR2007/052054 WO2008047023A2 (fr) | 2006-10-04 | 2007-10-02 | Methode d'immunisation contre les 4 serotypes de la dengue |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003417A true MX2009003417A (es) | 2009-04-09 |
Family
ID=38222583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003417A MX2009003417A (es) | 2006-10-04 | 2007-10-02 | Metodo de inmunizacion contra los 4 serotipos de dengue. |
Country Status (15)
Country | Link |
---|---|
US (2) | US7718358B2 (es) |
EP (3) | EP2526965A1 (es) |
JP (1) | JP5269796B2 (es) |
KR (1) | KR20090064593A (es) |
CN (2) | CN103285386A (es) |
AR (1) | AR063057A1 (es) |
AU (1) | AU2007311792B2 (es) |
BR (1) | BRPI0719849A2 (es) |
CA (1) | CA2663885A1 (es) |
FR (1) | FR2906724B1 (es) |
IL (2) | IL197768A0 (es) |
MX (1) | MX2009003417A (es) |
TW (2) | TW201336508A (es) |
WO (1) | WO2008047023A2 (es) |
ZA (1) | ZA200901816B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5227172B2 (ja) * | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
JP5689687B2 (ja) | 2008-03-05 | 2015-03-25 | サノフィ・パスツールSanofipasteur | アジュバント含有ワクチン組成物の安定化方法 |
EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
MY184428A (en) * | 2009-06-01 | 2021-04-01 | Inviragen Inc | Compositions and methods for administration of vaccines against dengue virus |
US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
CA2770888C (en) | 2009-08-31 | 2020-04-14 | Gen-Probe Incorporated | Dengue virus assay |
EP2353609A1 (en) * | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
WO2011119628A2 (en) | 2010-03-23 | 2011-09-29 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
AU2012275319A1 (en) * | 2011-06-29 | 2013-11-14 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection |
EP2858668A1 (en) * | 2012-06-10 | 2015-04-15 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
US8895028B2 (en) * | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
MX2015000446A (es) | 2012-07-24 | 2015-03-12 | Sanofi Pasteur | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue. |
MY168959A (en) * | 2012-07-24 | 2019-01-28 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
CA2933472A1 (en) | 2012-12-14 | 2014-06-19 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
CN105246506A (zh) | 2013-06-21 | 2016-01-13 | 默沙东公司 | 登革病毒疫苗组合物及其使用方法 |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
SG11201704942QA (en) | 2014-12-22 | 2017-07-28 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
CN108699534B (zh) * | 2015-11-27 | 2022-05-24 | Km生物医药股份公司 | 具有登革热病毒减毒株库的活病毒和包含其作为抗原的登革热疫苗 |
SG11202002933TA (en) | 2017-10-05 | 2020-04-29 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
MX2021002586A (es) | 2018-09-05 | 2021-06-08 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administracion de esta. |
AU2020331884A1 (en) | 2019-08-16 | 2022-03-03 | Takeda Vaccines, Inc. | Methods for preventing dengue and Hepatitis A |
EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
WO2024108087A1 (en) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
ES2345614T3 (es) | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
WO1999061916A1 (en) | 1998-05-29 | 1999-12-02 | Epimmune, Inc. | Identification of broadly reactive dr restricted epitopes |
JP2002540171A (ja) * | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱4型ウイルスワクチン |
CA2365728A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
CA2368790A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-3 virus vaccine |
WO2000057909A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
CN1191092C (zh) * | 1999-03-26 | 2005-03-02 | 沃尔特里德军事研究院 | 多价登革病毒疫苗 |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
EP3000477A1 (en) | 2000-02-16 | 2016-03-30 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Avirulent, immunogenic flavivirus chimeras |
EP1159969A1 (fr) | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
PT1159968E (pt) * | 2000-05-30 | 2008-11-20 | Univ Mahidol | Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina |
AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
ES2523168T3 (es) | 2001-05-22 | 2014-11-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos |
WO2002095007A2 (en) | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
CA2448971C (en) | 2001-06-01 | 2013-11-26 | Acambis, Inc. | Chimeric flavivirus vectors |
US20040120964A1 (en) * | 2001-10-29 | 2004-06-24 | Mikszta John A. | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
US7459160B2 (en) * | 2002-01-15 | 2008-12-02 | Acambis Inc. | Chimeric flaviviruses |
US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
CA2519953C (en) * | 2003-03-24 | 2016-01-05 | The Scripps Research Institute | Dna vaccine against tumor growth and methods of use thereof |
KR101536612B1 (ko) * | 2005-06-17 | 2015-07-14 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 1 균주 |
JP5227172B2 (ja) * | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-10-04 FR FR0608660A patent/FR2906724B1/fr not_active Expired - Fee Related
-
2007
- 2007-09-20 TW TW102119488A patent/TW201336508A/zh unknown
- 2007-09-20 TW TW096135167A patent/TWI406673B/zh not_active IP Right Cessation
- 2007-09-28 AR ARP070104316A patent/AR063057A1/es unknown
- 2007-10-02 BR BRPI0719849-3A2A patent/BRPI0719849A2/pt active Search and Examination
- 2007-10-02 CN CN201310128837XA patent/CN103285386A/zh active Pending
- 2007-10-02 MX MX2009003417A patent/MX2009003417A/es active IP Right Grant
- 2007-10-02 AU AU2007311792A patent/AU2007311792B2/en not_active Ceased
- 2007-10-02 EP EP11192672A patent/EP2526965A1/fr not_active Withdrawn
- 2007-10-02 CN CN2007800444299A patent/CN101553251B/zh not_active Expired - Fee Related
- 2007-10-02 KR KR1020097008657A patent/KR20090064593A/ko active IP Right Grant
- 2007-10-02 EP EP11192665A patent/EP2526964A1/fr not_active Withdrawn
- 2007-10-02 WO PCT/FR2007/052054 patent/WO2008047023A2/fr active Application Filing
- 2007-10-02 US US11/866,382 patent/US7718358B2/en not_active Expired - Fee Related
- 2007-10-02 JP JP2009530916A patent/JP5269796B2/ja not_active Expired - Fee Related
- 2007-10-02 CA CA002663885A patent/CA2663885A1/en not_active Abandoned
- 2007-10-02 EP EP07858487.7A patent/EP2077857B1/fr not_active Not-in-force
- 2007-10-02 ZA ZA200901816A patent/ZA200901816B/xx unknown
-
2009
- 2009-03-23 IL IL197768A patent/IL197768A0/en not_active IP Right Cessation
-
2010
- 2010-03-05 US US12/718,308 patent/US20100270202A1/en not_active Abandoned
-
2013
- 2013-02-04 IL IL224572A patent/IL224572A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP5269796B2 (ja) | 2013-08-21 |
JP2010505801A (ja) | 2010-02-25 |
IL224572A (en) | 2014-06-30 |
AU2007311792A1 (en) | 2008-04-24 |
IL197768A0 (en) | 2011-08-01 |
CN101553251B (zh) | 2013-05-22 |
TW201336508A (zh) | 2013-09-16 |
FR2906724A1 (fr) | 2008-04-11 |
FR2906724B1 (fr) | 2009-03-20 |
US20100270202A1 (en) | 2010-10-28 |
EP2526964A1 (fr) | 2012-11-28 |
BRPI0719849A2 (pt) | 2014-04-29 |
EP2077857B1 (fr) | 2013-11-20 |
CN103285386A (zh) | 2013-09-11 |
TWI406673B (zh) | 2013-09-01 |
WO2008047023A3 (fr) | 2008-10-23 |
TW200826959A (en) | 2008-07-01 |
ZA200901816B (en) | 2010-06-30 |
EP2526965A1 (fr) | 2012-11-28 |
EP2077857A2 (fr) | 2009-07-15 |
KR20090064593A (ko) | 2009-06-19 |
CN101553251A (zh) | 2009-10-07 |
CA2663885A1 (en) | 2008-04-24 |
AU2007311792B2 (en) | 2013-05-02 |
WO2008047023A2 (fr) | 2008-04-24 |
US7718358B2 (en) | 2010-05-18 |
AR063057A1 (es) | 2008-12-23 |
US20080085288A1 (en) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009003417A (es) | Metodo de inmunizacion contra los 4 serotipos de dengue. | |
MY169275A (en) | Method of immunization against the four serotypes of dengue | |
MY180698A (en) | Immunization protocol against the 4 dengue serotypes | |
PH12014501133A1 (en) | Compositions and methods for treating hepatitis c virus | |
NO20072733L (no) | Doseformer | |
TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
NO20055000L (no) | Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger | |
TN2009000481A1 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
NO20091954L (no) | Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido | |
MY148690A (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
AU2008267058A8 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
SG146643A1 (en) | Treating or preventing restless legs syndrome using prodrugs of gaba analogs | |
WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
ATE387912T1 (de) | Transepikutane darreichungsform zur behandlung des restless leg syndroms | |
JP2007508326A5 (es) | ||
BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
MX2007004004A (es) | Vacunas multivalentes contra la influenza aviar. | |
AR062248A1 (es) | Composiciones y metodos para tratar artritis reumatoidea | |
MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
RU2013120345A (ru) | Новые способы лечения инфекции, вызванной вирусом гепатита с | |
MX2022001742A (es) | Metodos para prevenir el dengue y la hepatitis a. | |
MD3121G2 (ro) | Metodă de profilaxie a hepatitei virale B |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |